We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Aptuit and GSK Extend Strategic Partnership

Read time: Less than a minute

Aptuit LLC has announced that the company has reached an agreement on a multiyear extension of its strategic partnership with GlaxoSmithKline (GSK) for dedicated drug development work at The Aptuit Center for Drug Discovery & Development in Verona, Italy.

The Verona site - formerly known as GSK’s Medicines Research Centre - was acquired by Aptuit from GSK in 2010.

Timothy C. Tyson, Chairman, Aptuit LLC said, "This multiyear extension of our partnership with GSK reaffirms that our Verona site continues to deliver scientific excellence that is recognized by our customers. Since we finalized our original agreement with GSK in 2010, we have successfully transformed the Verona site from a pharmaceutical research center to a world-class drug discovery and development outsourcing capability."

Mr. Tyson explained that during the two years since the Verona site became part of Aptuit it has effectively transitioned to a lean, flexible, customer-focused pharmaceutical services operation.

To date, the Verona site has had approximately 50 successful audits and has delivered work for more than 100 clients.

Mr. Tyson added, "Aptuit initiatives in Verona, such as Lean Six Sigma, are resulting in productivity benefits across our business lines. The high level of quality and regulatory compliance demonstrated in our work has been noticeable to the more than 200 customers who have visited the site since 2010."